GUARNERI, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.892
EU - Europa 1.662
AS - Asia 1.518
SA - Sud America 13
OC - Oceania 8
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 17.100
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.867
CN - Cina 650
IT - Italia 616
SG - Singapore 588
FI - Finlandia 309
SE - Svezia 236
FR - Francia 177
GB - Regno Unito 134
IN - India 106
VN - Vietnam 103
DE - Germania 85
HK - Hong Kong 33
IE - Irlanda 31
CA - Canada 25
NL - Olanda 16
BR - Brasile 10
UA - Ucraina 10
BE - Belgio 9
CZ - Repubblica Ceca 9
ES - Italia 9
PH - Filippine 8
MK - Macedonia 7
CH - Svizzera 5
KR - Corea 5
TR - Turchia 5
AU - Australia 4
EG - Egitto 4
JP - Giappone 4
NZ - Nuova Zelanda 4
IL - Israele 3
IR - Iran 3
NP - Nepal 2
SI - Slovenia 2
TW - Taiwan 2
AL - Albania 1
AT - Austria 1
BD - Bangladesh 1
CL - Cile 1
DK - Danimarca 1
EC - Ecuador 1
EU - Europa 1
HR - Croazia 1
ID - Indonesia 1
KZ - Kazakistan 1
MY - Malesia 1
OM - Oman 1
PE - Perù 1
PL - Polonia 1
RS - Serbia 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 17.100
Salva come PNG Salva come JPEG
Città #
Fairfield 2.653
Woodbridge 1.464
Houston 1.339
Chandler 1.098
Ashburn 1.094
Ann Arbor 979
Cambridge 884
Seattle 884
Wilmington 779
Singapore 448
San Diego 266
Medford 251
Princeton 251
Padova 229
Des Moines 208
Beijing 165
Helsinki 159
Nanjing 117
Roxbury 109
Dong Ket 102
Boardman 89
Santa Clara 88
Pune 70
New York 57
London 46
Milan 42
Shenyang 42
Guangzhou 37
Nanchang 33
Dublin 31
Hebei 29
Jinan 27
Ogden 26
Tianjin 26
Dallas 25
Rome 23
Jiaxing 22
Changsha 18
Norwalk 18
Ottawa 17
Columbus 16
Falls Church 16
Lappeenranta 15
Arezzo 14
Hong Kong 12
Kilburn 11
Venice 11
Los Angeles 10
Washington 10
Zhengzhou 10
Brussels 9
Codogno 9
Hounslow 9
Kharkiv 9
Turin 9
Chiswick 8
Olomouc 8
Vicenza 8
Haikou 7
Naples 7
Paris 7
Redwood City 7
Selvazzano Dentro 7
Stockholm 7
Tappahannock 7
Bologna 6
Hefei 6
New Bedfont 6
Pignone 6
Rubano 6
Amsterdam 5
Mumbai 5
Ningbo 5
Piove Di Sacco 5
Shanghai 5
Skopje 5
São Paulo 5
Verona 5
Acton 4
Borås 4
Capo d'Orlando 4
Chicago 4
Council Bluffs 4
Dronten 4
Enterprise 4
Florence 4
Islington 4
Lanzhou 4
Lucca 4
Southwark 4
Taiyuan 4
Todi 4
Ahmedabad 3
Avezzano 3
Bari 3
Bergamo 3
Falkenstein 3
Frankfurt am Main 3
Hamburg 3
Hangzhou 3
Totale 14.638
Salva come PNG Salva come JPEG
Nome #
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 179
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 172
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 143
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 140
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary 139
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 137
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 134
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis 132
In response to Jackson letter to the editor regarding safety of intravenous and oral bisphosphonates and compliance with dosing regimens 128
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 128
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 126
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab 123
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 123
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 123
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 122
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations 122
Immune characterization of breast cancer metastases: Prognostic implications 122
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 120
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 119
Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges 118
Escalation and de-escalation in HER2 positive early breast cancer 117
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 115
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 114
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 112
Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: Individual patient data meta-analysis 110
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials 110
Gastric Linitis Plastica and Peritoneal Carcinomatosis as First Manifestations of Occult Breast Carcinoma: A Case Report and Literature Review 110
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 107
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 106
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. 103
Rare breast cancer subtypes: histological, molecular, and clinical peculiarities 100
Olaparib for the treatment of breast cancer 100
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 100
Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? 99
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 98
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study 97
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 97
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 96
Fat grafting for breast cancer patients: From basic science to clinical studies 96
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study 93
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 92
Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies 91
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 91
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 91
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 90
Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy 90
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support 89
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 89
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study. 89
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer 89
Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study 88
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 87
Achievements and unmet needs in the management of advanced ovarian cancer 87
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 87
Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. 87
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 86
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 85
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 84
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis 83
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. 82
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer 82
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. 82
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma - Results from the Gruppo Oncologico Nord Ovest randomized trial 81
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 81
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden 81
Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents 81
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 81
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 80
Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis 80
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 79
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 78
The clinical relevance of endocrine therapy induced changes in lipid metabolism in breast cancer patients 78
Clinical utility of measuring circulating tumor cells in metastatic breast cancer 78
Controversies of chemotherapy for the treatment of metastatic breast cancer. 78
The curability of breast cancer and the treatment of advanced disease 77
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens 77
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer 77
Trastuzumab containing regimens for early breast cancer. 77
Biomarkers predicting clinical benefit: fact or fiction? 76
Mesenchymal Progenitors Expressing TRAIL Induce Apoptosis in Sarcomas 76
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma 76
Timing for starting second line therapy in recurrent ovarian cancer. 76
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 75
HER2-Positive Early Breast Cancer 75
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer 75
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 75
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study 74
The Issue of Renal Safety of Zoledronic Acid from a Nephrologist's Point of View 74
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. 74
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) 74
PIK3CA: a Target or a Marker in Breast Cancers 74
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 73
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 72
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 72
Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients 72
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis. 72
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives 72
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study. 71
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 71
Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. 70
Totale 9.534
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.623
article - articoli 75.947
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.106
Totale 154.676
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.675 0 0 90 466 325 192 287 330 396 293 183 113
2020/20212.994 93 162 91 143 135 549 296 196 372 368 271 318
2021/20223.568 155 396 432 199 306 246 284 273 215 116 263 683
2022/20232.371 483 225 109 279 319 248 48 148 325 35 118 34
2023/20241.683 100 194 161 121 103 237 129 90 92 79 178 199
2024/2025804 25 529 250 0 0 0 0 0 0 0 0 0
Totale 17.480